50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,661.61 (-0.86%)
DOW   29,293.20 (-1.00%)
QQQ   274.41 (-0.40%)
AAPL   150.74 (+0.21%)
MSFT   237.82 (-0.04%)
META   137.66 (-1.96%)
GOOGL   98.39 (-0.35%)
AMZN   115.25 (+1.29%)
TSLA   277.92 (+0.94%)
NVDA   122.99 (-1.73%)
NIO   17.80 (+0.91%)
BABA   79.24 (+0.56%)
AMD   66.65 (-1.93%)
T   15.67 (-2.12%)
MU   48.95 (-2.30%)
CGC   2.75 (-3.17%)
F   12.00 (-2.52%)
GE   64.49 (-0.09%)
DIS   98.38 (-1.13%)
AMC   7.11 (-11.01%)
PYPL   84.84 (-2.45%)
PFE   43.90 (-0.41%)
NFLX   223.48 (-1.29%)
S&P 500   3,661.61 (-0.86%)
DOW   29,293.20 (-1.00%)
QQQ   274.41 (-0.40%)
AAPL   150.74 (+0.21%)
MSFT   237.82 (-0.04%)
META   137.66 (-1.96%)
GOOGL   98.39 (-0.35%)
AMZN   115.25 (+1.29%)
TSLA   277.92 (+0.94%)
NVDA   122.99 (-1.73%)
NIO   17.80 (+0.91%)
BABA   79.24 (+0.56%)
AMD   66.65 (-1.93%)
T   15.67 (-2.12%)
MU   48.95 (-2.30%)
CGC   2.75 (-3.17%)
F   12.00 (-2.52%)
GE   64.49 (-0.09%)
DIS   98.38 (-1.13%)
AMC   7.11 (-11.01%)
PYPL   84.84 (-2.45%)
PFE   43.90 (-0.41%)
NFLX   223.48 (-1.29%)
S&P 500   3,661.61 (-0.86%)
DOW   29,293.20 (-1.00%)
QQQ   274.41 (-0.40%)
AAPL   150.74 (+0.21%)
MSFT   237.82 (-0.04%)
META   137.66 (-1.96%)
GOOGL   98.39 (-0.35%)
AMZN   115.25 (+1.29%)
TSLA   277.92 (+0.94%)
NVDA   122.99 (-1.73%)
NIO   17.80 (+0.91%)
BABA   79.24 (+0.56%)
AMD   66.65 (-1.93%)
T   15.67 (-2.12%)
MU   48.95 (-2.30%)
CGC   2.75 (-3.17%)
F   12.00 (-2.52%)
GE   64.49 (-0.09%)
DIS   98.38 (-1.13%)
AMC   7.11 (-11.01%)
PYPL   84.84 (-2.45%)
PFE   43.90 (-0.41%)
NFLX   223.48 (-1.29%)
S&P 500   3,661.61 (-0.86%)
DOW   29,293.20 (-1.00%)
QQQ   274.41 (-0.40%)
AAPL   150.74 (+0.21%)
MSFT   237.82 (-0.04%)
META   137.66 (-1.96%)
GOOGL   98.39 (-0.35%)
AMZN   115.25 (+1.29%)
TSLA   277.92 (+0.94%)
NVDA   122.99 (-1.73%)
NIO   17.80 (+0.91%)
BABA   79.24 (+0.56%)
AMD   66.65 (-1.93%)
T   15.67 (-2.12%)
MU   48.95 (-2.30%)
CGC   2.75 (-3.17%)
F   12.00 (-2.52%)
GE   64.49 (-0.09%)
DIS   98.38 (-1.13%)
AMC   7.11 (-11.01%)
PYPL   84.84 (-2.45%)
PFE   43.90 (-0.41%)
NFLX   223.48 (-1.29%)
NASDAQ:ALLK

Allakos - ALLK Stock Forecast, Price & News

$5.78
+0.53 (+10.10%)
(As of 09/26/2022 02:34 PM ET)
Add
Compare
Today's Range
$5.59
$6.47
50-Day Range
$3.14
$5.84
52-Week Range
$2.54
$11.73
Volume
117,228 shs
Average Volume
1.63 million shs
Market Capitalization
$317.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$66.80

Allakos MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
1,074.0% Upside
$66.80 Price Target
Short Interest
Bearish
6.77% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.58mentions of Allakos in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$20 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($6.05) to ($2.95) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

94th out of 1,069 stocks

Pharmaceutical Preparations Industry

28th out of 533 stocks

ALLK stock logo

About Allakos (NASDAQ:ALLK) Stock

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.

Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Stock News Headlines

Allakos Inc. (NASDAQ:ALLK) Short Interest Up 7.1% in August
Why Is Allakos (ALLK) Stock Soaring 25% Today?
See More Headlines
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Company Calendar

Last Earnings
8/04/2022
Today
9/26/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALLK
Fax
N/A
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$66.80
High Stock Price Forecast
$155.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+1,055.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
11 Analysts

Profitability

Net Income
$-269,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.20 per share

Miscellaneous

Free Float
36,608,000
Market Cap
$317.00 million
Optionable
Not Optionable
Beta
0.66

Key Executives

  • Dr. Robert Alexander Ph.D.Dr. Robert Alexander Ph.D. (Age 52)
    CEO & Director
    Comp: $1.39M
  • Dr. Adam L. Tomasi Ph.D. (Age 52)
    Pres & COO
    Comp: $1.06M
  • Mr. Baird Radford III
    Chief Financial Officer
  • Meg Fitzgerald
    Sr. VP, Gen. Counsel, Sec. and Chief Compliance Officer
  • Dr. Henrik Sandvad Rasmussen (Age 63)
    Strategic Advisor
  • Dr. Craig Paterson M.D.
    Chief Medical Officer
  • Brad Youngblood
    Head of Research
  • Mr. Alan Chang
    Director of Medical Affairs & Data Analytics













ALLK Stock - Frequently Asked Questions

Should I buy or sell Allakos stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 2 sell ratings, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALLK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares.
View ALLK analyst ratings
or view top-rated stocks.

What is Allakos' stock price forecast for 2022?

11 Wall Street analysts have issued twelve-month price objectives for Allakos' stock. Their ALLK share price forecasts range from $13.00 to $155.00. On average, they predict the company's stock price to reach $66.80 in the next year. This suggests a possible upside of 1,011.5% from the stock's current price.
View analysts price targets for ALLK
or view top-rated stocks among Wall Street analysts.

How have ALLK shares performed in 2022?

Allakos' stock was trading at $9.79 at the beginning of the year. Since then, ALLK shares have decreased by 38.6% and is now trading at $6.01.
View the best growth stocks for 2022 here
.

When is Allakos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our ALLK earnings forecast
.

How were Allakos' earnings last quarter?

Allakos Inc. (NASDAQ:ALLK) announced its earnings results on Thursday, August, 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.05.

What other stocks do shareholders of Allakos own?
When did Allakos IPO?

(ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and William Blair was co-manager.

What is Allakos' stock symbol?

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Who are Allakos' major shareholders?

Allakos' stock is owned by a variety of retail and institutional investors. Top institutional investors include Millennium Management LLC (3.44%), Federated Hermes Inc. (3.21%), Price T Rowe Associates Inc. MD (1.13%), JPMorgan Chase & Co. (1.12%), Renaissance Technologies LLC (1.05%) and Clearline Capital LP (1.02%). Insiders that own company stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James.
View institutional ownership trends
.

How do I buy shares of Allakos?

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allakos' stock price today?

One share of ALLK stock can currently be purchased for approximately $6.01.

How much money does Allakos make?

Allakos (NASDAQ:ALLK) has a market capitalization of $329.61 million. The company earns $-269,860,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis.

How many employees does Allakos have?

The company employs 192 workers across the globe.

How can I contact Allakos?

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for the company is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at ir@allakos.com.

This page (NASDAQ:ALLK) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.